Phase 1 Trial to Determine the Recommended Phase 2 Dose (RP2D) of VX-970 When Combined With Whole Brain Radiotherapy (WBRT) in Patients With Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase I
Latest Information Update: 16 Aug 2017
At a glance
- Drugs M 6620 (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 25 Jul 2016 Status changed from not yet recruiting to recruiting.
- 17 Jul 2016 Planned primary completion date changed from 1 Jun 2017 to 1 Sep 2018.